Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors

Authors: Escobar, M; Agrawal, N; Chatterjee, S; Bhattacharya, S; Caicedo, J; Bullano, M; Schultz, BG

Affiliations: University of Texas Health Science Center, Houston, Texas, USA. Complete HEOR Solutions, North Wales, PA. Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA.

Publication: Journal of medical economics; 2023. 1–24

Abstract: BACKGROUND: Factor VIII (FVIII) replacement and emicizumab are effective at preventing bleeds in patients with hemophilia A (HA). Though benefits of emicizumab among inhibitor patients with HA (PwHA) are well established, more real-world evidence among non-inhibitor patients is needed. METHODS: Using a United States healthcare claims database, we compared billed annualized bleed rates (ABR(b)) and the total cost of care (TCC) before and after switching from FVIII prophylaxis to emicizumab among non-inhibitor male PwHA. Bayesian inferences were used to assess the difference in ABR(b) and TCC per patient per year (PPPY) pre versus post prophylaxis switch. We included 101 non-inhibitor males PwHA aged between 3 and 63 years old who switched from FVIII prophylaxis to emicizumab prophylaxis in 2018 or 2019. RESULTS: The ABR(b) increased from 0.52 to 0.62 (p = 0.83) after switch. The posterior probability of the mean ABR(b) increasing after the switch was 75.54%. The TCC PPPY increased from $517,143 to $627,005 (p < 0.0001) after switch and the posterior probability of mean costs increasing after the switch was 99.80%. CONCLUSIONS: Personalization of care through the identification of the most appropriate therapy for each patient can optimize clinical and economic outcomes. Future real-world evidence research could help establish the value of prophylactic options in targeted populations such as the non-inhibitor male PwHA.